nach oben

Erschienen in:

01.07.2021 | News item

Risk of serotonin syndrome when bupropion administered with SRIs

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

The Australian Therapeutic Goods Administration (TGA) is advising healthcare professionals that Product Information for buproprion products has been updated with the risk of serotonin syndrome when bupropion is co-administered with serotonin reuptake inhibitors (SRIs) including selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (NSRIs). If concomitant treatment with other serotonergic agents is clinically warranted, the patient should be carefully monitored, says the TGA. …

Therapeutic Goods Administration. Medicines Safety Update - Bupropion and serotonin syndrome Internet Document : 2 Jul 2021. Available from: URL: https://www.tga.gov.au/publication-issue/bupropion-and-serotonin-syndrome

Titel: Risk of serotonin syndrome when bupropion administered with SRIs
Publikationsdatum: 01.07.2021
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-021-98935-6

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Risk of serotonin syndrome when bupropion administered with SRIs

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Ipilimumab/nivolumab/pembrolizumab

Lacosamide/levetiracetam

Natalizumab

Nitrous-oxide abuse

Pembrolizumab

Selinexor